RBC Capital notes that that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulation patent for Nuplazid, while also rejecting Aurobindo’s arguments of invalidity. The firm and investors now have further reassurance on Nuplazid’s out-year defensibility, with tail revenues potentially protected to 2038, says the analyst, who has an Outperform rating and $26 price target on Acadia shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia confirms court ruling in favor of Nuplazid formulation patent
- ACADIA Pharmaceuticals: Strengthened Patent Position and Growth Prospects Drive Buy Rating
- Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer
- Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital
- Acadia Pharmaceuticals price target raised to $30 from $27 at Needham